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ABSTRACT 
 
Background: While liver-related deaths in HIV and hepatitis C virus (HCV) co-infected individuals 
have declined over the last decade, hepatocellular carcinoma (HCC) may have increased. We de-
scribed the epidemiology of HCC and other liver events in a multi-cohort collaboration of HIV/HCV 
co-infected individuals. 
 
Methods: We studied all HCV antibody-positive adults with HIV in the EuroSIDA Study, the South-
ern Alberta Clinic Cohort, the Canadian Co-infection Cohort, and the Swiss HIV Cohort Study from 
2001 to 2014. We calculated the incidence of HCC and other liver events (defined as liver-related 
deaths or decompensations, excluding HCC) and used Poisson regression to estimate incidence rate 
ratios. 
 
Results: Our study comprised 7,229 HIV/HCV co-infected individuals (68% male, 90% white). Dur-
ing follow-up, 72 cases of HCC and 375 other liver events occurred, yielding incidence rates of 1.6 
(95% confidence interval (CI): 1.3, 2.0) and 8.6 (95% CI: 7.8, 9.5) cases per 1,000 person-years of 
follow-up, respectively. The rate of HCC increased 11% per calendar year (95% CI: 4%, 19%) and 
decreased 4% for other liver events (95% CI: 2%, 7%), but only the latter remained statistically sig-
nificant after adjustment for potential confounders. High age, cirrhosis, and low current CD4 cell 
count were associated with a higher incidence of both HCC and other liver events.  
 
Conclusions: In HIV/HCV co-infected individuals, the crude incidence of HCC increased from 2001 
to 2014, while other liver events declined. Individuals with cirrhosis or low current CD4 cell count are 
at highest risk of developing HCC or other liver events. 
 
  
TEXT 
 
 
BACKGROUND 
As hepatitis C virus (HCV) and human immunodeficiency virus (HIV) have shared 
modes of transmission, individuals with HIV are more often infected with HCV than the general pop-
ulation [1]. HCV can cause chronic hepatic inflammation leading to liver fibrosis and cirrhosis that 
entails a risk of liver decompensation and hepatocellular carcinoma (HCC) [2]. Concomitant HIV 
infection accelerates this process [3, 4]. It is therefore not surprising that liver disease is one of the 
main causes of death in people with HIV [5]. Some studies indicate that the overall rate of liver-
related death is declining in HIV/HCV co-infected individuals [6], but at the same time, national co-
hort studies have shown an increasing rate of HCC [7-9].  
We aimed to study HIV/HCV co-infected individuals in Europe and Canada and de-
scribe trends in the incidence of HCC and other liver events from 2001 to 2014 and identify risk fac-
tors for the development of HCC and other liver events.  
 
 
METHODS 
Study population 
We included all HIV/HCV co-infected individuals in four prospective cohorts of HIV-
positive individuals: the EuroSIDA study [10], which enrolls HIV-positive individuals from 107 clin-
ics across Europe, Israel, and Argentina; the Southern Alberta Clinic Cohort [11], which enrolls indi-
viduals receiving HIV care in Southern Alberta, Canada; the Canadian Co-infection Cohort study 
(CTN222) [12], which enrolls HCV co-infected HIV-positive individuals from 18 centers across Can-
ada; and the Swiss HIV Cohort Study [13], which enrolls HIV-positive individuals from Switzerland. 
All cohorts collect and update data at least every six months using standardized collection forms. 
 We defined HCV co-infection as being HCV antibody-positive. Baseline was defined 
as the latest of first cohort or clinic visit; first positive HCV antibody-test; or January 1, 2001 (since 
data on non-AIDS defining cancers, including HCC, were collected prospectively from this date). 
Data from all participating cohorts were pooled together by use of the HIV Cohort Da-
ta Exchange Protocol [14], which is freely available at www.hicdep.org. 
 
Outcomes 
We studied two separate outcomes: 1) HCC, and 2) other liver events, defined as liver 
decompensation or liver-related death. Liver decompensation was defined as hepatic encephalopathy 
(grade 3 or 4), hepatorenal syndrome, ascites, variceal bleeding, or spontaneous bacterial peritonitis. 
Liver-related death was defined as deaths caused by chronic viral hepatitis or other liver failure, ex-
cluding HCC. The diagnoses were based on pathology reports, hospital discharge summaries, or con-
sultation notes from the hospitalization or clinic. For HCC, in the absence of the above, the diagnosis 
could also be based on a strong suspicion supported by evidence from radiological imaging or bio-
chemical assay. All events were subsequently centrally reviewed. 
 
Statistical analysis 
Crude incidence rates of both HCC and other liver events were calculated by calendar 
time, grouped into two-year periods, and stratified by latest cirrhosis status and CD4 cell count, also 
testing for interaction between cirrhosis status and current CD4 cell count. 
Poisson generalized estimating equations assuming auto-regressive (AR1) correlation 
were used to investigate the association between various demographic, HIV, and lifestyle related 
characteristics and the incidence of HCC and other liver related events, separately. Variables signifi-
cant in the univariate regression models (P<0.1) were included in the multivariate regression models. 
Sensitivity analyses were performed which excluded HCC cases with HIV/HCV/HBV co-infection or 
those with any cancer diagnosis (other than HCC) prior to end of follow-up.  
  All statistical tests were two sided with a type I error rate of 5%. Statistical analyses 
were performed using SAS 9.3 (Statistical Analysis Software, Cary NC, USA). 
 
Predictor variables 
The following variables were considered for inclusion in the regression models: age, 
sex*, race* (white, other/unknown), region* (Europe East/Argentina, Europe West, Canada), HIV 
risk group* (men who have sex with men (MSM), injection drug use (IDU), heterosexual, oth-
er/unknown), body mass index (BMI) category, ever smoked, ever abused alcohol, diabetes mellitus, 
hepatitis B virus (HBV) co-infection, ever HBV active drugs, ever HCV active drugs, ever combina-
tion antiretroviral therapy (cART), ever acquired immunodeficiency syndrome (AIDS), detectable 
HIV RNA, CD4 cell count current (per doubling), CD4 cell count nadir, cirrhosis, and calendar year 
of event*. Asterisks indicate time-fixed variables; all other variables were updated at each visit.  
BMI was calculated as weight in kilograms / squared height in meters and categorized 
as either underweight (BMI <20), normal weight (BMI 20-25), overweight (BMI 25-30), or obese 
(BMI > 30). Alcohol use was not uniformly collected in all cohorts, but where available, alcohol 
abuse was defined as consuming above 25 units per week for men and 20 units per week for women. 
Diabetes mellitus was defined as having a diagnosis of insulin-dependent diabetes mellitus or taking 
diabetic medication or insulin. HBV co-infection was defined as the presence of hepatitis B surface 
antigen in serum. cART was defined as receiving at least three antiretrovirals from any class. Detect-
able HIV RNA was defined as having plasma HIV RNA above 400 copies per milliliter.  
Cirrhosis was defined using a hierarchical structure using cutoffs from earlier publica-
tions [15-17]: A liver biopsy with a METAVIR score of F4 was considered the highest level of evi-
dence, followed by a FibroScan elasticity of 12.5 kPa or above, then an aspartate aminotransferase-to-
platelet ratio index (APRI) of 2 or above, and then a plasma hyaluronic acid level of 200 ng/ml or 
above. The individual patient was assumed cirrhotic from the date of measurement and onwards if the 
measurement fulfilled at least one of the criteria mentioned above. If different markers were incon-
 sistent, the marker of highest evidence level decided the cirrhosis status. Individuals in whom we 
could not assess cirrhosis status were classified as “missing”. 
 
 
RESULTS 
Baseline characteristics 
We included 7,229 individuals in our study (4,132 from the EuroSIDA Study; 2,044 
from the Swiss HIV Cohort Study; 840 from the Canadian Co-infection Cohort; 213 from the South-
ern Alberta Clinic Cohort). Table 1 shows the baseline characteristics of our study population. The 
majority were male (68%), white (90%), and primarily from Europe West (58%). Median age was 38 
(inter-quartile range (IQR): 36, 43) years. The main HIV risk group was IDU (59%), and 5% were 
HIV/HCV/HBV co-infected. 
 
Incidence rates of HCC and other liver events 
From 2001 to 2014, 72 cases of HCC (with 45,192 person-years of follow-up) and 375 
cases of other liver events (with 43,718 person-years of follow-up) occurred, resulting in overall inci-
dence rates of 1.6 (95% confidence interval (CI): 1.3, 2.0) cases of HCC per 1,000 person-years of 
follow-up and 8.6 (95% CI: 7.8, 9.5) cases of other liver events per 1,000 person-years of follow-up. 
Figure 1 shows the incidence rates of HCC and other liver events as a function of calendar years. The 
incidence of HCC increased by 11% per year (95% CI: 4%, 19%, p = 0.002), from 0.4 cases per 1,000 
person-years of follow-up in 2001-02 to 2.3 cases per 1,000 person-years of follow-up in 2013-14. In 
contrast, the incidence of other liver events decreased by 4% per year (95% CI: 2%, 7%, p = 0.002) 
from 9.9 cases per 1,000 person-years of follow-up in 2003-04 to 5.2 cases per 1,000 person-years of 
follow-up in 2013-14.  
In individuals with cirrhosis, the overall incidence rate of HCC was 7.9 (95% CI: 5.9, 
10.5) cases per 1,000 person-years of follow-up against 0.5 (95% CI: 0.3, 0.7) cases per 1,000 person-
years of follow-up in individuals who did not have cirrhosis according to our definition. For other 
 liver events, the incidence rates were 35.9 (95% CI: 31.1, 41.4) and 2.4 (95% CI: 1.9, 3.0) cases per 
1,000 person-years of follow-up in cirrhotics and non-cirrhotics, respectively.  
When further stratifying for current CD4 cell count, we found that the incidence rates 
of both outcomes were lower in those with a current CD4 cell count above 350 cells/mm3 in both 
those with and without cirrhosis (Figure 2). For individuals with cirrhosis, the incidence rate of HCC 
decreased from 10.9 (95% CI: 7.4, 16,1) cases per 1,000 person-years of follow-up in those with a 
CD4 cell count below 350 cells/mm3 to 6.1 (95% CI: 3.8, 9.7) cases per 1,000 person-years of follow-
up in those with a CD4 cell count above 350 cells/mm3. For other liver events, the effect of current 
CD4 cell count was more drastic, as the incidence rate here went from 58.7 (95% CI: 49.2, 70.0) to 
20.1 (95% CI: 15.5, 26.4) cases per 1,000 person-years of follow-up, respectively. Formal statistical 
interaction analyses did not identify a significant interaction between cirrhosis and current CD4 cell 
count for any outcome (both p > 0.2), but the analyses had low power. 
 
Characteristics at event 
Table 2 shows the characteristics at event in those who developed HCC or other liver 
events and at end-of-follow-up in the remaining cohort. Median age at event was 49.6 years for HCC 
versus 43.9 years for other liver events. Within two years of event, 75% of those who developed HCC 
and 70% of those who developed other liver events had cirrhosis. Only 8% of HCC cases and 6% of 
other liver events cases were HBV co-infected. 32% of those who developed HCC had ever taken 
HCV active drugs versus 18% of those who developed other liver events. Almost all had ever taken 
cART (99% of HCC cases and 91% of other liver events cases), but their most recent (within six 
months) CD4 cell counts were however still quite low with a median of 286 (IQR: 201, 438) 
cells/mm3 for those who developed HCC and 242 (IQR: 110, 397) cells/mm3 for those who developed 
another liver event. 
Of the 11 of those who developed HCC that had an HCV RNA measurement at least 
six months after completing interferon-based treatment, none had achieved a sustained virologic re-
sponse (SVR). 
  
Risk factors for HCC and other liver events 
In multivariate analysis of HCC (Table 3), higher age, HBV co-infection, lower current 
CD4 cell count, and cirrhosis were associated with a higher incidence of HCC. Notably, we found no 
impact of alcohol abuse, diabetes mellitus, or detectable HIV RNA on the incidence of HCC in uni-
variate analysis. 
Later calendar years were significantly associated with a higher incidence of HCC 
events in univariate analysis, but not in multivariate analysis, indicating that changes in some of the 
other variables explained the increase over time. In a supplementary analysis, increases in the propor-
tion with cirrhosis mostly explained the increase in HCC over time, as it was only after adjustment for 
cirrhosis that there no longer was a significant increase in HCC over time (adjusted incidence rate 
ratio per calendar year increase 1.05, 95% CI: 0.98, 1.13). 
The multivariate analysis of other liver events yielded similar risk factors (Figure 3 and 
Supplementary Table 1): higher age, lower CD4 cell count, and cirrhosis (but not HBV co-infection) 
were associated with a higher incidence of other liver events. However, the HIV risk group “oth-
er/unknown” compared with MSM, being underweight, and having ever smoked were also significant 
risk factors for other liver events. The decrease in other liver events per calendar year in the univariate 
analysis did remain significant in multivariate analysis. 
Excluding those with HBV co-infection or those with any other cancer diagnosis prior 
to end-of-follow-up did not change the results (data not shown). 
 
 
DISCUSSION 
We observed opposing trends in the incidence of HCC and other liver events in 
HIV/HCV co-infected individuals from 2001 to 2014: HCC increased from 0.4 to 2.3 cases per 1,000 
person-years of follow-up, whereas other liver events decreased from 9.9 to 5.2 cases per 1,000 per-
son-years of follow-up.  
 The increase in HCC incidence has previously been shown in national and mostly ret-
rospective studies of HIV/HCV co-infected individuals: in Spain, Merchante et al. [8] showed that the 
incidence increased from 2000 to 2010 (0.2 to 1.4 cases per 1,000 person-years of follow-up), and, in 
a study of the Veterans Affairs Cohort in the United States, Ioannou et al. [9] found that the age-
adjusted prevalence of HCC increased from 0.15% in 1996 to 1.06% in 2009. The authors of these 
studies point to the increased survival in individuals with HIV as an explanation for the rise in inci-
dence, as HCV-related development of cirrhosis and subsequent HCC takes several years [18]. Our 
results support this reasoning as changes in the proportion of individuals with cirrhosis – which we 
found to increase by 8% per year in a post-hoc analysis (data not shown) – mostly explained the in-
crease in HCC per calendar year in multivariate analysis. 
However, while the proportion of cirrhotics and incidence of HCC was increasing, we 
found that the incidence of other liver events, i.e. liver decompensations and liver-related deaths, de-
creased. Other recent studies of HIV/HCV co-infected individuals, but not all [19], have shown simi-
lar trends [5-7, 20]. This could potentially be explained by the increased uptake of cART, which has 
been found to lower the progression of hepatic fibrosis and disease [21, 22], improved HCV treatment 
uptake [23], and possibly the switch from older hepatotoxic antiretrovirals such as zidovudine, dida-
nosine, and stavudine to newer drugs [24]. In our analysis, prior cART and and prior HCV active drug 
treatment did not impact on the decrease of other liver events per calendar year in multivariate analy-
sis, but an increase of CD4 cell count did protect against the development of other liver events, and 
the population as a whole had higher CD4 cell counts at end-of-follow-up. Improvements in HIV and 
HCV treatment have undoubtedly reduced the risk of liver decompensations or liver-related death in 
the last decade, but our data suggest that other explanatory factors are yet to be accounted for.  
Thus, taken together, our study has shown opposing shifts in the incidence of HCC and 
other liver events. It seems paradoxical that improvements in liver-related morbidity in HIV/HCV co-
infected patients, demonstrated by a lower incidence of other liver events, would at the same time 
yield a higher incidence of HCC. One explanation could be that an improved management of liver 
cirrhosis and HIV treatment can increase the threshold for liver decompensation in the cirrhotic 
 HIV/HCV co-infected individuals, but thus increasing longevity to a point where viral hepatocarcino-
genesis has had enough time to manifest itself as HCC. This hypothesis is somewhat supported in our 
finding that for cirrhotics, the decrease in incidence rate was much more pronounced for other liver 
events than for HCC when comparing those with a current CD4 cell count less than 350 cells/mm3 to 
those with a count above 350 cells/mm3, though formal analysis for interaction between cirrhosis and 
current CD4 cell count was not statistically significant.  
In our multivariate analysis, the major risk factor for HCC was cirrhosis. We found that 
74% of individuals with HCC had cirrhosis within six months of HCC diagnosis. As “missing” cir-
rhosis status also was associated with a higher incidence of HCC, it is likely that the markers used in 
our definition of cirrhosis have not identified all true cirrhotics, rather than an actual situation in 
which 26% of individuals developed HCC without cirrhosis. However, as liver biopsies are being 
continuously replaced by the same non-invasive markers, our results warns that HCC can develop in 
individuals who do not seem to have cirrhosis based on these markers.  
We also found that lower current CD4 cell count was associated with HCC in 
HIV/HCV co-infected individuals. Previous studies have also shown this in HIV individuals in gen-
eral [9, 25, 26], but in HCV/HIV co-infected individuals, the results have been conflicting: Salmon et 
al. [27] did not find an association, arguing that any association is likely confounded by cirrhosis as 
concomitant splenic sequestration of lymphocytes artificially lowers the CD4 cell count [28]. But in a 
more recent study, Kramer et al. [29] found that having a CD4 cell count of <200 cells/mm3 (com-
pared with >350 cells/mm3) was associated with a 1.7 times greater hazard of HCC, and the associa-
tion remained when analyzing a subgroup with cirrhosis. In our study – where we treated CD4 cell 
count as a continuous variable – we found a statistically significant protective effect of a doubling in 
current CD4 cell count after adjustment for cirrhosis, corroborating the independent effect of current 
immunosuppression as a risk factor of HCC. 
In addition to cirrhosis and CD4 cell count, HBV co-infection and higher age were sig-
nificant risk factors for HCC. All these are clinically relevant parameters that can help the treating 
physician assess each HIV/HCV co-infected individual’s risk of liver malignancy. However, the risk 
 factors we identified for HCC were also independent risk factors for other liver events (except for 
HBV co-infection). The effect sizes were different, but for a singular case, the clinician should per-
ceive the aforementioned risk factors as more general predictors of liver disease and death, and not 
HCC exclusively, especially as the incidence of HCC, though increasing, remains low. 
Our study has several limitations: First, our diagnosis of cirrhosis was based primarily 
on non-invasive techniques. However, the measurements and their respective cutoffs have been vali-
dated [30], and possible misclassifications would underestimate any real effect of cirrhosis in our 
analyses, where it in fact was the strongest predictor. Second, we defined (chronic) HCV co-infection 
by the presence of HCV antibodies, and as around 20% can clear the infection spontaneously, we 
might have included some individuals with resolved HCV infection. Third, data on alcohol abuse 
were only recently added to some of our cohorts and thus very limited. The major strength of our 
study is that our population is taken from prospective cohorts, representing a large portion of Europe 
and Canada and with a relatively large proportion of females rendering our results readily applicable 
to the Caucasian population. 
In conclusion, we observed that from 2001 to 2014, the incidence of HCC in HIV/HCV 
co-infected individuals increased – largely explained by an increase in the number of individuals with 
cirrhosis – whereas the rate of other liver events (liver decompensations and liver-related deaths) de-
creased. Higher age, cirrhosis, and lower current CD4 cell counts were independent risk factors for 
both HCC and other liver events. New treatment of HCV with direct acting antivirals and earlier HIV 
treatment will likely reduce the rates of HCC and other liver events, but as HCC still can develop after 
achieving SVR [31], or as a consequence of long-tern alcohol abuse, non-alcoholic steatohepatitis or 
other hepatotoxic exposures, continuous surveillance of incidence trends is needed. 
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 Table 1.  Baseline Characteristics of 7,229 HIV/Hepatitis C Virus Co-Infected Individuals 
Characteristic  
Age, years, median (IQR) 38.1 (32.6, 43.4) 
Female sex, N (%) 2,304 (31.9) 
White race, N (%) 6,530 (90.3) 
Region, N (%)  
Europe West 4,200 (58.1) 
Europe East/Argentina 1,976 (27.3) 
Canada 1,053 (14.6) 
HIV risk group, N (%)  
Men who have sex with men 834 (11.5) 
Injection drug use 4,289 (59.3) 
Heterosexual 1,188 (16.4) 
Other/unknown 918 (12.7) 
BMI category, N (%)a  
Underweight 111 (4.1) 
Normal weight 2,003 (74.5) 
Overweight 496 (18.5) 
Obese 78 (2.9) 
Ever smoked, N (%)b 2,168 (71.7) 
Ever abused alcohol, N (%)c 165 (13.3) 
Diabetes mellitus, N (%) 200 (2.8) 
HBV co-infection, N (%)d 329 (5.1) 
Ever HBV active drugs, N (%) 381 (5.3) 
Ever HCV active drugs, N (%) 735 (10.2) 
Ever cART, N (%) 5,138 (71.1) 
 Ever AIDS, N (%) 1,822 (25.2) 
Detectable HIV RNA, N (%)f 2,540 (41.6) 
CD4 cell count, cells/mm3, median (IQR)g 388 (240, 571) 
CD4 cell count nadir, cells/mm3, median (IQR)h 208 (95, 351) 
Cirrhosis, N (%)i 342 (5.9) 
Year of baselinej, N (%)   
2001-02 3,185 (44.1) 
2003-04 799 (11.1) 
2005-06 892 (12.3) 
2007+ 2,353 (32.5) 
Abbreviations: IQR, inter-quartile range; BMI, body mass index; AIDS, acquired immunodeficiency 
syndrome; cART, combination antiretroviral therapy; HCV, hepatitis C virus; HBV, hepatitis B virus. 
a Body mass index was categorized in 2,668 individuals. 
b Smoking status was determined in 3,025 individuals. 
c Alcohol abuse was determined in 1,241 individuals.  
d HBV co-infection was determined in 6,485 individuals. 
f Detectable HIV RNA was determined in 6,099 individuals. 
g CD4 cell count was determined in 6,802 individuals. 
h CD4 cell count nadir was determined in 7,098 individuals. 
i Cirrhosis was determined in 5,799 individuals. 
j Baseline was defined as the latest of first visit; first positive HCV-antibody test; or January 1, 2001. 
 
 
  
Table 2.  Characteristics of HIV/Hepatitis C Virus Co-Infected Individuals Within Six 
Months of Diagnosis of Hepatocellular Carcinoma or Other Liver Event or Within Six Months 
of End-of-Follow-Up in the Remaining Cohort 
Characteristic No HCC or other 
liver event  
(n = 6,787) 
HCC  
(n = 72) 
Other liver event  
(n = 375) 
Age, years, median (IQR) 44.8 (37.6, 50.8) 49.6 (46.0, 55.8) 43.9 (38.6, 49.6) 
Follow-up time, years, median 
(IQR) 
5.3 (2.5, 9.7) 6.0 (2.4, 9.2) 3.9 (1.6, 6.7) 
Female sex, N (%) 2,182 (32.1) 17 (23.6) 106 (28.3) 
White race, N (%) 6,124 (90.2) 68 (94.4) 343 (91.5) 
Region, N (%)    
Europe West 3,882 (57.2) 55 (76.4) 266 (70.9) 
Europe East/Argentina 1,898 (28.0) 6 (8.3) 73 (19.5) 
Canada 1,007 (14.8) 11 (15.3) 36 (9.6) 
HIV risk group, N (%)    
Men who have sex with men 802 (11.8) 6 (8.3) 27 (7.2) 
Injection drug use 4,003 (59.0) 40 (55.6) 249 (66.4) 
Heterosexual 1,129 (16.6) 17 (23.6) 43 (11.5) 
Other/unknown 853 (12.6) 9 (12.5) 56 (14.9) 
BMI category, N (%)a    
Underweight 179 (6.8) 3 (12.0) 23 (13.9) 
Normal weight 1,794 (68.6) 17 (68.0) 109 (65.7) 
Overweight 527 (20.2) 4 (16.0) 27 (16.3) 
Obese 115 (4.4) 1 (4.0) 7 (4.2) 
Ever smoked, N (%)b 2987 (80.1) 25 (75.8) 180 (86.5) 
 Ever abused alcohol, N (%)c 610 (18.6) 4 (20.0) 22 (30.6) 
Diabetes mellitus, N (%) 313 (4.6) 6 (8.3)  29 (7.7)  
HBV co-infection, N (%)d  292 (4.5) 6 (8.3) 23 (6.3) 
Ever HBV active drugs, N (%) 2,633 (38.8) 34 (47.2) 136 (36.3) 
Ever HCV active drugs, N (%) 1,537 (14.6) 23 (31.9) 68 (18.1) 
Ever cART, N (%) 5,964 (87.9) 71 (98.6) 340 (90.7) 
Ever AIDS, N (%) 2,163 (31.9) 28 (38.9)  167 (44.5)  
Detectable HIV RNA, N (%)e 1,189 (25.1) 9 (15.5) 123 (38.4) 
CD4 cell count current, 
cells/mm3, median (IQR)f 
470 (289, 670) 286 (201, 438) 242 (110, 397) 
Cirrhosis, N (%)h 1,447 (25.0) 45 (75.4) 189 (69.7) 
Abbreviations: HCC, hepatocellular carcinoma; IQR, inter-quartile range; BMI, body mass index; 
AIDS, acquired immunodeficiency syndrome; cART, combination antiretroviral therapy; HBsAg, 
hepatitis B surface antigen; HCV, hepatitis C virus; HBV, hepatitis B virus; APRI, aspartate ami-
notransferase-to-platelet ratio index. 
a Body mass index was categorized in 2,615 individuals without an event, 25 individuals with HCC, 
and 166 individuals with other liver events. 
b Smoking status was determined in 3,728 individuals without an event, 33 individuals with HCC, and 
208 individuals with other liver events. 
c Alcohol abuse was determined in 3,278 individuals without an event, 20 individuals with HCC, and 
72 individuals with other liver events.  
d HBV co-infection was determined in 6,489 individuals without an event, 69 individuals with HCC, 
and 366 individuals with other liver events. 
e Detectable HIV RNA was determined in 4,746 individuals without an event, 58 individuals with 
HCC, and 320 individuals with other liver events. 
f CD4 cell count current was determined in 6,254 individuals without an event, 69 individuals with 
HCC, and 349 individuals with other liver events. 
 g CD4 cell count nadir was recorded in 6,773 individuals without an event, all individuals with HCC 
and 370 individuals with other liver events. 
h Cirrhosis was determined in 5,799 individuals without an event, 61 individuals with HCC, and 271 
individuals with other liver events.
  
Table 3.  Univariate and Multivariate Analyses of Hepatocellular Carcinoma in 
HIV/Hepatitis C Virus Co-Infected Individuals 
 Univariate analysis Multivariate analysisa 
 IRR (95% CI) p-value IRR (95% CI) p-value 
Age at baseline, per 10 year in-
crease 
2.43 (2.06, 2.88) < 0.01 2.36 (1.89, 2.94) < 0.01 
Sex, female vs. male 0.61 (0.36, 1.06) 0.08 1.01 (0.58, 1.77) 0.96 
Race, other/unknown vs. white 0.65 (0.24, 1.77) 0.40   
Region     
Europe West Reference  Reference  
Europe East/Argentina 0.32 (0.14, 0.74) 0.01 0.65 (0.28, 1.51) 0.31 
Canada 1.27 (0.6, 2.42) 0.47 0.68 (0.32, 1.45) 0.32 
HIV risk group     
Men who have sex with men Reference    
Injection drug use 1.06 (0.45, 2.50) 0.89   
Heterosexual 1.79 (0.71, 4.51) 0.22   
Other/unknown 1.07 (0.38, 3.01) 0.89   
BMI category     
Underweight 2.40 (0.70, 8.22) 0.16   
Normal weight Reference    
Overweight 0.91 (0.31, 2.71) 0.87   
Obese 1.26 (0.17, 9.39) 0.82   
Unknown 1.14 (0.65, 1.98) 0.65   
Ever smoked     
No Reference    
 Yes 0.84 (0.38, 1.85) 0.66   
Unknown 1.07 (0.50, 2.28) 0.87   
Ever abused alcohol     
No Reference    
Yes 1.34 (0.45, 4.01) 0.61   
Unknown 0.66 (0.38, 1.15) 0.14   
Diabetes mellitus, yes vs. no 1.95 (0.86, 4.46)  0.11   
HBV co-infection     
No Reference  Reference  
Yes 2.17 (0.94, 5.02) 0.07 2.46 (1.03, 5.87) 0.04 
Unknown 0.72 (0.23, 2.28) 0.58 0.96 (0.31, 2.96) 0.95 
Ever HBV active drugs, yes vs. no 1.92 (1.12, 3.04)  < 0.01 1.00 (0.59, 1.68) 0.99 
Ever HCV active drugs, yes vs. no 2.06 (1.26, 3.38)   < 0.01 1.27 (0.74, 2.16)  0.39 
Ever cART, yes vs. no 12.03 (1.67, 86.58)  < 0.01 5.79 (0.77, 43.69)  0.09 
Ever AIDS, yes vs. no 1.51 (0.94, 2.42) 0.09 1.20 (0.69, 2.06) 0.52 
Detectable HIV RNA     
No Reference    
Yes 0.56 (0.28, 1.14) 0.11   
Unknown 0.83 (0.46, 1.50) 0.53   
CD4 cell count current, per log2 
increase in cells/mm3 
 
0.74 (0.66, 0.83) 
 
< 0.01 
 
0.78 (0.65, 0.95) 
 
0.01 
CD4 cell count nadir, per log2 
increase in cells/mm3 
 
0.88 (0.80, 0.97) 
 
< 0.01 
 
1.07 (0.90, 1.27) 
 
0.43 
Cirrhosis     
No Reference    
Yes 17.21 (9.74, 30.41) < 0.01 12.92 (6.97, 23.95) < 0.01 
 Unknown 5.51 (2.56, 11.87) < 0.01 5.80 (2.52, 13.39) < 0.01 
Calendar year of event, per year 
increase 
 
1.11 (1.04, 1.19) 
 
< 0.01 
 
1.05 (0.98, 1.13) 
 
0.17 
Abbreviations: IRR, incidence rate ratio; CI, confidence interval; BMI, body mass index; AIDS, ac-
quired immunodeficiency syndrome; HCV, hepatitis C virus; HBV, hepatitis B virus; cART, combi-
nation antiretroviral therapy. 
a Variables with a p-value of < 0.10 in the univariate analysis were included in the multivariate analy-
sis. 
  
FIGURE LEGENDS 
 
Figure 1 Trend in Incidence Rates (with 95% Confidence Intervals) of Hepatocellular Carcino-
ma and Other Liver Events in 7,229 HIV/Hepatitis C Virus Co-Infected Individuals from 2001 to 
2014 
 
Figure 2 Incidence Rates (with 95% Confidence Intervals) for Hepatocellular Carcinoma and 
Other Liver Events in HIV/Hepatitis C Virus Co-Infected Individuals Stratified by Cirrhosis Status 
and Current CD4 Cell Count (Cells per mm3). Note: Formal Analysis of Interaction between Cirrhosis 
and Current CD4 Cell Count was Non-Significant for Both Outcomes (All P-values > 0.2) 
 
Figure 3 Adjusted Incidence Rate Ratios (with 95% Confidence Intervals) for a Selection of 
Risk Factors for Hepatocellular Carcinoma (HCC) and Other Liver Events in Multivariate Time-
Updated Poisson Regression Models 
